바이오스펙테이터

바이오스펙테이터 Sungmin Kim 기자

Enactment of a joint research agreement with Ajou University Medical Center in CNS Neurodegenerative Diseases and Regeneration field... "Planning to announce the interim results of new non-narcotic pa

Olipass will expand their treatment field in the existing anti-cancer drug pipeline to central nervous system (CNS) disease for the new drug development pipeline in earnest. CEO of Olipass, Chung Shin said that "I think CNS will be the next generation in the new drug development field. In order to expand the pipeline in the CNS sector, we have signed a strategic business agreement with an Ajou University Medical center with expertise in that field.

"Past CNS drugs were mainly low-molecular compounds, and they were more empirical approaches to developing new drugs than target-specific ones," said CEO Chung. "We determined that Olipass' technologies for the oligonucleotide PNA(Peptide Nucleic Acid) platform have advantages in that they are capable of delivering CNS with target-specific approach." Olipass plans to secure new pipelines in CNS and Alzheimer's disease. Their Olipass PNA platform operates as a mechanism for regulating exon skipping which can control pre-mRNA expression.

To secure the CNS pipeline in full scale, Olipass signed a memorandum of understanding (MOU) with Ajou University Medical Center on the 23rd to create achievements through academic exchanges, research and development, and cooperation between industry and academic circles. Participants in the conference included Park Hae-sim, president of Ajou University's Institute of Advanced Medicine, Kim Byung-gon, professor of the department of biomedical science graduate school, Hwang Dong-hoon, chairman of the Department of Brain Science, Chung Shin, CEO of Olipass, Vice President Lee Jang-young, director Cho Bong-joon, and director Kim Jong-wan.

Through this agreement, the both organizations will actively cooperate on following things: joint research in neurodegenerative diseases and regenerative fields, innovative medical research and development, joint use of each other’s research facilities, human resources development and support in the field of biomedical science, network, and matters related to relationship between the two organizations.

“Under the agreement, the two organizations will build new pipelines through joint research in neurodegenerative diseases and regenerative fields, and strengthen cooperation in such areas as research on validity using experimental animals and human resources exchange.” said Park Hae-sim, president of Ajou University's Institute of Advanced Medicine.

Meanwhile, for an Olipass' lead project progress, the company completed single and repeated administration (s.c.) at the U.K. Clinical Ia phase of SCN9A inhibitor 'OLP-1002' developed as a non-narcotic painkiller late last year (NCT03760913). Olipass is undergoing a clinical trial in which up to 160μg of medication is administered to obtain additional drug safety data.

Based on the clinical results, Ollipass plans to submit an IND of clinical Ib phase for patients with osteoarthritis next month to Australian regulatory. "We expect that OLP-1002's clinical interim results will come out in the second half, and accordingly, will discuss technology exports around that time." Chung explained.

Founded in November 2006, Olipass has secured their own platform technology for making oligonucleotide that has excellent permeability and is conducting development of new RNA treatment drugs for such diseases as pain, hypercholesterolemia, macular degeneration, diabetes, and solid cancer.